Immunotherapy in atopic dermatitis.
Immunotherapy
; 14(14): 1149-1164, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-2268835
ABSTRACT
In the past decade, the emergence of biologics targeting human cytokine networks has advanced a new era in atopic dermatitis therapy. Dupilumab, in particular, the most widely studied and used IL-4/IL-13 inhibitor, has been considered a milestone in the treatment of patients with moderate-to-severe atopic dermatitis. In addition to the IL-4 and IL-13 pathways, many other cytokines and receptors have been newly targeted as therapeutic options. In this review, the authors provide an overview of the approved and tested biologics and JAK inhibitors for the treatment of atopic dermatitis, including their advantages and limitations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Dermatitis, Atopic
Limits:
Humans
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
Imt-2022-0054
Similar
MEDLINE
...
LILACS
LIS